Loan & DebtJun 29, 2026, 08:01 AM
4D Molecular Therapeutics Secures $200M Credit Facility
AI Summary
4D Molecular Therapeutics has entered into a strategic credit facility agreement with Hercules Capital, Inc. for up to $200 million. This non-dilutive capital is expected to increase the company's financial strength and provide operational flexibility, extending its cash runway into the second half of 2028. The company drew an initial $20 million at closing, with additional tranches available upon meeting certain conditions.
Key Highlights
- Secured a strategic credit facility agreement for up to $200 million.
- Drew an initial $20 million at closing of the facility.
- An additional $30 million is available through June 15, 2027.
- $100 million is available upon achievement of certain milestones.
- Cash, cash equivalents, and marketable securities were $458 million as of March 31, 2026.
- Expected to fund operations into the second half of 2028, excluding this facility.
Price Impact
More from FDMT